New Ovarian Cancer Marker Identified
Author Information
Author(s): K. Ohkawa, Y. Tsukada, M. Murae, E. Kimura, K. Takada, T. Abel, Y. Terashima, K. Mitani
Primary Institution: Jikei University School of Medicine
Hypothesis
Can a new monoclonal antibody effectively identify ovarian carcinoma-associated antigens?
Conclusion
The CF511 antigen is a promising new marker for diagnosing and managing ovarian carcinoma.
Supporting Evidence
- CF511 antigen levels were elevated in 25 of 36 ovarian cancer patients.
- 100% of patients with advanced ovarian cancer had elevated CF511 levels.
- CF511 antigen was also found in patients with breast and lung cancer.
Takeaway
Scientists found a new marker in the blood that can help doctors tell if someone has ovarian cancer. This marker is found more in people with advanced cancer.
Methodology
The study involved immunizing mice with human fetal tissue and ovarian cancer cell lines to produce a monoclonal antibody, followed by testing serum samples from patients.
Potential Biases
Potential bias in the selection of patient samples and the specificity of the antibody.
Limitations
The CF511 antigen is not specific to ovarian cancer, as it is also elevated in breast and lung cancer patients.
Participant Demographics
Patients included those with common epithelial ovarian carcinoma, breast carcinoma, lung carcinoma, and benign gynecological diseases.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website